ARTICLE | Finance
Longitude takes a spin with Cydan
Why Longitude funded Cydan's latest spinout to makeover an Ipsen asset
January 5, 2019 12:39 AM UTC
Longitude Capital's first foray into a Cydan Development Inc. spinout came Thursday when Cydan launched Tiburio Therapeutics Inc. to repurpose TBR-760 (formerly BIM-23A760) from Ipsen Group (Euronext:IPN; Pink:IPSEY), eight years after the compound's false start in acromegaly.
Longitude's Sandip Agarwala told BioCentury the mechanism of action that tripped up BIM-23A760 in acromegaly gives the dopamine-somatostatin chimeric molecule significant potential in non-functioning pituitary adenoma (NFPA)...